Bacterial contamination of needles used for intravitreal injections: a prospective, multicenter study.
Stewart
Jay M
JM
University of California, San Francisco, Department of Ophthalmology, San Francisco, California, USA. stewartj@vision.ucsf.edu
Srivastava
Sunil K
SK
Fung
Anne E
AE
Mahmoud
Tamer H
TH
Telander
David G
DG
Hariprasad
Seenu M
SM
Ober
Michael D
MD
Mruthyunjaya
Prithvi
P
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy; D003430:Cross-Sectional Studies; D003930:Diabetic Retinopathy / Q000188:drug therapy; D009877:Endophthalmitis / Q000382:microbiology; D004866:Equipment Contamination; D015818:Eye Infections, Bacterial / Q000453:epidemiology* / Q000382:microbiology*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections / Q000009:adverse effects / Q000295:instrumentation*; D008268:Macular Degeneration / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009339:Needles / Q000009:adverse effects / Q000382:microbiology*; D011206:Povidone-Iodine / Q000008:administration & dosage; D011425:Propionibacterium acnes / Q000302:isolation & purification; D011446:Prospective Studies; D000069579:Ranibizumab; D013212:Staphylococcus epidermidis / Q000302:isolation & purification; D014822:Vitreous Body / Q000382:microbiology
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D011206:Povidone-Iodine; D000069579:Ranibizumab